These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36863717)
1. Response to article - alternative interpretation of "there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome". Tobacyk J; Brents LK J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183469. PubMed ID: 36863717 [No Abstract] [Full Text] [Related]
2. There is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome. Townsel C; Odukoya E; Rae J; Thomas D J Matern Fetal Neonatal Med; 2022 Dec; 35(25):9227-9233. PubMed ID: 34978244 [TBL] [Abstract][Full Text] [Related]
4. A review of the literature: How does prenatal opioid exposure impact placental health and fetal brain development? Humphries A; Simcox K; Howell B Dev Psychobiol; 2023 Apr; 65(3):e22378. PubMed ID: 36946682 [TBL] [Abstract][Full Text] [Related]
6. [Neonatal abstinence syndrome after maternal use of tramadol]. de Wit D; Koomen-Botman I Ned Tijdschr Geneeskd; 2013; 157(9):A5610. PubMed ID: 23446156 [TBL] [Abstract][Full Text] [Related]
7. The placenta as a target of opioid drugs†. Rosenfeld CS Biol Reprod; 2022 Apr; 106(4):676-686. PubMed ID: 35024817 [TBL] [Abstract][Full Text] [Related]
8. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863 [TBL] [Abstract][Full Text] [Related]
12. Fetal gastric area ratio to predict severe neonatal opioid withdrawal syndrome. Townsel C; Stone J; Debolt C; Hussain N; Campbell WA J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7957-7961. PubMed ID: 34151686 [TBL] [Abstract][Full Text] [Related]
13. Drug addiction during pregnancy: correlations between the placental health and the newborn's outcome - elaboration of a predictive score. Domenici C; Cuttano A; Nardini V; Varese L; Ghirri P; Boldrini A Gynecol Endocrinol; 2009 Dec; 25(12):786-92. PubMed ID: 19905997 [TBL] [Abstract][Full Text] [Related]
14. Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. Jones HE; Kaltenbach K; Benjamin T; Wachman EM; O'Grady KE J Addict Med; 2019; 13(2):90-92. PubMed ID: 30334926 [TBL] [Abstract][Full Text] [Related]
15. Opioids affect the fetal brain: reframing the detoxification debate. Caritis SN; Panigrahy A Am J Obstet Gynecol; 2019 Dec; 221(6):602-608. PubMed ID: 31323217 [TBL] [Abstract][Full Text] [Related]
16. Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review. Shan F; MacVicar S; Allegaert K; Offringa M; Jansson LM; Simpson S; Moulsdale W; Kelly LE Trials; 2020 Mar; 21(1):262. PubMed ID: 32164782 [TBL] [Abstract][Full Text] [Related]
17. Accuracy of diagnostic codes for prenatal opioid exposure and neonatal opioid withdrawal syndrome. Kuzniewicz MW; Campbell CI; Li S; Walsh EM; Croen LA; Comer SD; Pimentel SD; Hedderson M; Sun LS J Perinatol; 2023 Mar; 43(3):293-299. PubMed ID: 36131095 [TBL] [Abstract][Full Text] [Related]
19. Maternal and iatrogenic neonatal opioid withdrawal syndrome: Differences and similarities in recognition, management, and consequences. Isaac L; van den Hoogen NJ; Habib S; Trang T J Neurosci Res; 2022 Jan; 100(1):373-395. PubMed ID: 33675100 [TBL] [Abstract][Full Text] [Related]
20. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. de Castro A; Jones HE; Johnson RE; Gray TR; Shakleya DM; Huestis MA Clin Chem; 2011 Mar; 57(3):449-58. PubMed ID: 21245372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]